|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07D 401/14 | |
| A61K 31/506 | |||
| A61P 35/00 |
| (11) | Patento numeris | 2186808 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 10150322.5 |
| Europos patento paraiškos padavimo data | 2006-07-18 | |
| (97) | Europos patento paraiškos paskelbimo data | 2010-05-19 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2017-04-19 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| 701406 P | 2005-07-20 | US | |
| 716213 P | 2005-09-12 | US |
| (72) |
Manley, Paul, CH
Shieh, Wen-Chung, US
Sutton, Paul Allen, US
Karpinski, Plotr H., US
Wu, Raeann, US
Monnier, Stéphanie, FR
Brozio, Jörg, CH
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
Novartis Pharma AG, Brunner Strasse 59, 1230 Vienna, AT |
| (54) | Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
| Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |